下一代糖尿病药物输送市场规模、份额和成长分析（按产品、人口统计、适应症、最终用户和地区划分）—2026-2033年产业预测

全球下一代糖尿病药物输送市场预计到 2024 年将达到 393.1 亿美元，到 2025 年将达到 425.8 亿美元，到 2033 年将达到 805.7 亿美元，预测期（2026-2033 年）的复合年增长率为 8.3%。

受全球糖尿病盛行率不断上升的推动，新一代糖尿病药物传输系统的全球市场正经历强劲成长。市场对兼具有效性、便利性和微创性的创新治疗方法有着显着的需求。治疗重点正从单纯控制血糖转向促进减重、改善心血管健康和提升整体生活品质的治疗方法，这推动了广泛的研发投入。然而，挑战依然存在，例如这些先进治疗方法和设备的高成本，严重阻碍了医保报销和患者的可及性。此外，漫长而高成本的监管核准流程也构成了另一道障碍，而真正实现非侵入性或可靠的「闭合迴路」系统仍然是糖尿病综合管理面临的一项重大技术挑战。

推动全球下一代糖尿病药物传递市场发展的因素

全球新一代糖尿病药物传输市场的显着扩张主要受1型和2型糖尿病患者数量大幅成长的驱动。不断成长的患者群体需要更有效率、更便捷的治疗方案，从而催生了对创新治疗解决方案的巨大需求。随着越来越多的人寻求有效控制病情的方法，对高效且能改善患者体验的先进药物输送系统的需求日益迫切。糖尿病盛行率的持续上升凸显了该领域发展的迫切性，推动了市场的不断进步和发展机会。

全球下一代糖尿病药物输送市场面临的限制因素

全球新一代糖尿病药物输送市场面临的主要挑战之一是治疗方法和医疗设备的高成本，这往往超出了许多患者的经济承受能力。这种经济负担阻碍了患者获得治疗，尤其是在新兴市场，因为在这些地区，从公共和私人保险公司获得报销极其困难。因此，保险覆盖范围的限制使得患者无法获得必要的治疗，最终限制了治疗选择，并加剧了糖尿病治疗的不平等。这些经济限制对创新糖尿病治疗方法的广泛应用构成了重大障碍。

下一代糖尿病治疗药物传递的全球市场趋势

全球下一代糖尿病药物输送市场正日益受到医疗设备间互通性和互联性的推动。患者在将持续血糖监测 (CGM) 设备与胰岛素帮浦配合使用时，越来越希望获得个人化的体验，这推动了对开放式通讯协定系统的需求。这一趋势提高了糖尿病管理的柔软性和使用者控制权，并透过个人化治疗促进了更好的治疗效果。随着医疗保健朝向更一体化的数位化环境发展，製造商正在投资开发智慧、扩充性的解决方案，以实现设备间的无缝通讯。这种技术融合不仅赋予病人更多自主权，也推动了市场创新和竞争格局的演变。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球下一代糖尿病药物传输市场规模（按产品和复合年增长率划分）（2026-2033 年）

• 吸入式胰岛素
• 口服胰岛素
• 胰岛素贴剂
• CGM系统
• 人工胰臟

全球下一代糖尿病药物传输市场规模（按人口统计和复合年增长率划分）（2026-2033 年）

• 成年人口（14岁以上）
• 儿童人口（14岁以下）

全球下一代糖尿病药物传输市场规模（按适应症和复合年增长率划分）（2026-2033 年）

• 1型糖尿病
• 2型糖尿病

全球下一代糖尿病药物传输市场规模（按最终用户划分）及复合年增长率（2026-2033 年）

• 诊断/诊所
• 加护病房（ICU）
• 家庭医疗保健

全球下一代糖尿病药物传输市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Novo Nordisk A/S（Denmark）
• Medtronic Plc（Ireland）
• Abbott Laboratories（United States）
• Dexcom, Inc.（United States）
• Eli Lilly and Company（United States）
• Sanofi（France）
• Insulet Corporation（United States）
• Tandem Diabetes Care, Inc.（United States）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• MannKind Corporation（United States）
• Becton, Dickinson and Company（BD）（United States）
• Ypsomed AG（Switzerland）
• Senseonics Holdings, Inc.（United States）
• Diabeloop SAS（France）
• Beta Bionics, Inc.（United States）
• Embecta Corp.（United States）
• Biocon Limited（India）
• Nemaura Medical Inc.（United Kingdom）
• Novartis AG（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）

结论与建议

Global Next Generation Diabetes Therapy Drug Delivery Market size was valued at USD 39.31 Billion in 2024 and is poised to grow from USD 42.58 Billion in 2025 to USD 80.57 Billion by 2033, growing at a CAGR of 8.3% during the forecast period (2026-2033).

The global market for next-generation diabetes therapy and drug delivery is experiencing robust growth fueled by the rising prevalence of diabetes worldwide. There exists a significant demand for innovative treatments that prioritize effectiveness, convenience, and minimal invasiveness. The focus is shifting from mere glucose management to therapies that promote weight loss, enhance cardiovascular health, and improve overall quality of life, driving extensive research and development initiatives. Nonetheless, challenges persist, including the high costs associated with these advanced therapies and devices, which present significant reimbursement and access hurdles. Additionally, navigating the lengthy and costly regulatory approval processes poses further obstacles, while the pursuit of truly non-invasive or reliable "closed loop" systems remains a technical challenge critical for comprehensive diabetes management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Next Generation Diabetes Therapy Drug Delivery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Next Generation Diabetes Therapy Drug Delivery Market Segments Analysis

Global Next Generation Diabetes Therapy Drug Delivery Market is segmented by Product, Demographic, Indication, End User and region. Based on Product, the market is segmented into Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas. Based on Demographic, the market is segmented into Adult Population (>14years) and Child Population (14years). Based on Indication, the market is segmented into Type 1 Diabetes and Type 2 Diabetes. Based on End User, the market is segmented into Diagnostic/Clinics, ICUs and Home Healthcare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Next Generation Diabetes Therapy Drug Delivery Market

The remarkable expansion of the global diabetes therapy drug delivery market is primarily driven by the significant increase in the number of people diagnosed with Type 1 and Type 2 diabetes. This growing population of patients necessitates enhanced and more convenient management options, creating a substantial demand for innovative therapeutic solutions. As more individuals seek effective ways to manage their condition, the need for advanced drug delivery systems that offer greater efficiency and improved patient experiences becomes increasingly critical. The ongoing rise in diabetes prevalence underscores the urgency for development in this sector, fueling ongoing advancements and opportunities within the market.

Restraints in the Global Next Generation Diabetes Therapy Drug Delivery Market

One significant challenge facing the Global Next Generation Diabetes Therapy Drug Delivery market is the high cost of therapies and devices, which often surpasses the financial capabilities of many patients. This economic burden creates a barrier to access, particularly in emerging markets where securing reimbursement from public and private payers proves to be incredibly difficult. As a result, the limited availability of insurance coverage hampers the ability of patients to obtain essential treatments, ultimately restricting their options and increasing disparities in diabetes care. These financial constraints pose a considerable obstacle to the widespread adoption of innovative diabetes therapies.

Market Trends of the Global Next Generation Diabetes Therapy Drug Delivery Market

The global next-generation diabetes therapy drug delivery market is increasingly shaped by the surge in interoperability and connectivity among medical devices. Patients are seeking more personalized experiences by combining continuous glucose monitors (CGMs) with insulin pumps, which fosters the demand for open-protocol systems. This trend enhances flexibility and user control in diabetes management, promoting better outcomes through tailored therapies. As healthcare moves toward a more integrated digital landscape, manufacturers are investing in smart, scalable solutions that facilitate seamless communication between devices. This convergence of technology not only empowers patients but also drives innovation and competitive dynamics within the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Next Generation Diabetes Therapy Drug Delivery Market Size by Product & CAGR (2026-2033)

• Market Overview
• Inhalable Insulin
• Oral Insulin
• Insulin Patches
• CGM Systems
• Artificial Pancreas

Global Next Generation Diabetes Therapy Drug Delivery Market Size by Demographic & CAGR (2026-2033)

• Market Overview
• Adult Population (>14years)
• Child Population (14years)

Global Next Generation Diabetes Therapy Drug Delivery Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Type 1 Diabetes
• Type 2 Diabetes

Global Next Generation Diabetes Therapy Drug Delivery Market Size by End User & CAGR (2026-2033)

• Market Overview
• Diagnostic/Clinics
• ICUs
• Home Healthcare

Global Next Generation Diabetes Therapy Drug Delivery Market Size & CAGR (2026-2033)

• North America (Product, Demographic, Indication, End User)
  • US
  • Canada
• Europe (Product, Demographic, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Demographic, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Demographic, Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Demographic, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dexcom, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tandem Diabetes Care, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MannKind Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ypsomed AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Senseonics Holdings, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Diabeloop SAS (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beta Bionics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Embecta Corp. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nemaura Medical Inc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations